)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
AdAlta
AdAlta (1AD) investor relations material
AdAlta H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary21 Aug, 2026
Executive summary
Clinical-stage biotech focused on next-gen cellular immunotherapies for solid cancers and protein therapeutics using proprietary i-body® platform.
Launched 'East to West' strategy, securing first asset EW-001 (anti-PD1 armoured CAR-T for mesothelioma) via partnership with Shanghai Cell Therapy Group.
Raised A$5.3 million across three placements to fund development and operations.
Continued partnering efforts for AD-214 (fibrosis) and WD-34 (malaria), with patent coverage expanded.
Financial highlights
Net loss after tax: $4,683,849 (2025: $4,502,268), reflecting increased R&D and licensing payments.
Cash at year-end: $1.28 million (2025: $1.31 million).
R&D tax incentive income: $404,245 (2025: $677,010).
Raised $5.3 million in equity placements; repaid $0.41 million in convertible debt.
No dividends declared or paid.
Outlook and guidance
Key milestones for FY2027: Australian manufacturing runs and clinical trials for EW-001, US FDA pre-IND meeting, further asset acquisitions, and potential partnering/licensing deals for AD-214 and WD-34.
Ongoing focus on capital efficiency, asset-level financing, and leveraging AI for asset selection and development planning.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AdAlta
- Lead CAR-T asset delivers strong results in mesothelioma, with scalable growth and partnering pipeline.1AD
Investor presentation - Asian CAR-T innovation for solid tumors is rapidly commercialized in the West via a capital-efficient, de-risked model.1ADInvestor presentation
- Asian clinical assets are advanced for Western markets, with AD-214 ready for partnering.1ADStatus Update
- BZDS1901 CAR-T achieves rare, durable responses in mesothelioma, targeting a $4.2B+ market.1ADInvestor update
- Strong early CAR-T results in mesothelioma, but cash runway remains a key risk.1ADQ3 2026 TU
- Transformation to cellular immunotherapies advances, but losses and funding risks persist.1ADH2 2025
- Completed Phase I for AD-214, expanded pipeline, raised capital, but faces ongoing funding risks.1ADH2 2024
- Major CAR-T collaboration launched, loss narrowed, and $2.8M raised amid ongoing R&D focus.1ADH1 2026
- Improving CAR-T access requires innovation, local manufacturing, and regulatory adaptation.1ADInvestor presentation
Next AdAlta earnings date
H1 202718 Feb, 2027
AdAlta
Next AdAlta earnings date
H1 202718 Feb, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage